Semaglutide leads to greater weight loss in women than men with HF, improves HF symptoms in both sexes
Key Findings:
Weight Loss: Women lost 9.6% of their body weight on average with semaglutide, compared with 7.2% in men, marking a significant difference.
Symptom Improvement: Both sexes saw notable improvements in HF symptoms, physical limitations, and exercise function.
Heart Failure Benefits Beyond Weight Loss: Despite greater weight loss in women, the improvement in HF symptoms was similar between sexes, suggesting semaglutide's heart failure benefits may be, in part, independent of weight loss.
WASHINGTON (June 23, 2024) – Semaglutide, a medication initially developed for ...













